Evidence map›Paper›PMID 40637996›Full record

ArticleDigestive diseases and sciences2025

Cystic Duct Stenting Versus Other Treatment Modalities for the Management of Acute Cholecystitis in Patients with Decompensated Cirrhosis.

Muhammad Saad Faisal, Kevin B Harris, Muhammad Salman Faisal, Taha Ashraf, Muhammad Shahzil, Muhammad Zarrar Khan, Ammad J Chaudhary, Andrew Watson, Duyen Dang, Robert Pompa and 4 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Muhammad Saad FaisalDepartment of Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI, 48202, USA. Mfaisal2@hfhs.org.
Kevin B HarrisDepartment of Transplant Hepatology, Mayo Clinic, Rochester, MN, USA.
Muhammad Salman FaisalDepartment of Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI, 48202, USA.
Taha AshrafDepartment of Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI, 48202, USA.
Muhammad ShahzilDepartment of Internal Medicine, Milton S. Hershey Medical Center, The Pennsylvania State University, Hershey, PA, USA.
Muhammad Zarrar KhanDepartment of Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI, 48202, USA.
Ammad J ChaudharyDepartment of Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI, 48202, USA.
Andrew WatsonDepartment of Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI, 48202, USA.
Duyen DangDepartment of Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI, 48202, USA.
Robert PompaDepartment of Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI, 48202, USA.
Mazen ElatracheDepartment of Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI, 48202, USA.
Cyrus PirakaDepartment of Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI, 48202, USA.
Sumit SinglaDepartment of Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI, 48202, USA.
Tobias ZuchelliDepartment of Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI, 48202, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsThe incidence of cholecystitis and cholelithiasis is higher in patients with cirrhosis. Decompensated liver disease places them at higher risk for morbidity and mortality from cholecystectomy, and many providers prefer non-surgical approaches. We compared cystic duct stenting (CDS) to other modalities mainly percutaneous cholecystostomy (PC), cholecystectomy, and medical management. METHODOLOGY: We performed a retrospective cohort study. After obtaining IRB approval, we gathered records of all patients at our health care system who had acute cholecystitis on presentation and an underlying diagnosis of cirrhosis with MELD-Na ≥ 15 from 2015 to 2022. Outcomes included 30-day mortality, 60-day mortality, 1-year mortality, 30-day readmission, and worsening liver disease as characterized by increasing MELD-Na by ≥ 3 or new onset ascites or encephalopathy following management.

results67 patients met our inclusion criteria. 19 patients had CDS and were compared to 48 patients managed by other modalities, i.e., cholecystectomy (n = 12), PC (n = 17) and medical management (n = 19). There was no difference in demographics, etiology of cirrhosis, or mean MELD-Na between the two groups. We noticed a significant difference in the protective effect of CDS on one-month readmission rate and liver function with RR of 0.56 (0.4-0.9, P = 0.038) and RR 0.49 (CI 0.3-0.8, P = 0.01), respectively. The only complication in the cystic duct stent group was one case of pancreatitis (5.2%).

conclusionFor patients with decompensated cirrhosis who present with acute cholecystitis, CDS via ERCP prevents readmissions and further decompensation of liver disease when compared to other treatment modalities.

Indexed as

CholecystectomyCholecystitis, AcuteCystic DuctLiver CirrhosisStentsAgedCholecystostomyFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeCholecystitisCystic ductDecompensated cirrhosisEndoscopic retrograde cholangiopancreatography (ERCP)

Identifiers

PMID40637996

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.